Brought to you by 
Santen gets Asian option to Parion Sciences' dry eye candidate
02 May 2017
Executive Summary
Parion Sciences Inc. licensed Santen Pharmaceutical Co. Ltd. an exclusive option to develop and commercialize the dry eye candidate P321 in certain Asian territories.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Santen gets Asian option to Parion Sciences' dry eye candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice